Document is current
Any future updates will be listed below
-
Authors
Puthenparampil, Marco https://orcid.org/0000-0002-2313-8462
Miscioscia, Alessandro
Basili, Elisa
Mauceri, Valentina Annamaria
Pengo, Marta
Torresin, Tommaso
De Napoli, Federica
Pilotto, Elisabetta
Rinaldi, Francesca
Perini, Paola
Midena, Edoardo
Gallo, Paolo
-
Funding
Funding for this research was provided by:
Università degli Studi di Padova
- License Information
-
More Information
Article History
Received: 4 March 2025
Accepted: 30 October 2025
First Online: 14 November 2025
Declarations
:
: The study was conducted in agreement with the Declaration of Helsinki and approved by the local Ethic Committee (Comitato Etico per la Sperimentazione Clinica dell’Azienda Ospedaliera di Padova, prot.n. 17760).
: Not applicable.
: MPu, reports travel grants, consultancy, and board membership from Almirall, Teva, Sanofi Genzyme, Merck Serono, Biogen Italy, Novartis, Bristol Myers Squibb, Janssen, and Alexion. Reports grant for Merck Serono, Roche, Sandoz, and Alexion. AM, EB, VMM, MPe, TT, FDN, EP, ME have nothing to disclose. RF reports grants from Almirall, Teva, Sanofi Genzyme, Merck Serono, Biogen Italy, Novartis; consultancy for Novartis, Biogen Italy, Sanofi Genzyme. PP reports grants from Almirall, Teva, Sanofi Genzyme, Merck Serono, Biogen Italy, Novartis, Roche; consultancy for Novartis, Biogen Italy, Sanofi Genzyme, Roche. PG reports grant, consultancy, and board membership for Almirall, Teva, Sanofi Genzyme, Merck Serono, Biogen Italy, Novartis, Roche, Bristol Myers Squibb, Janssen, and Alexion.
